医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Premas, IncellDx Ink India Distribution Agreement

2018年01月17日 PM02:01
このエントリーをはてなブックマークに追加


 

NEW DELHI

Premas Life Sciences Pvt., Ltd. and IncellDx, Inc. announced today they have signed an exclusive distribution agreement. The commercial partnership brings the power of cell by cell multiplex diagnostics for solid tumors carcinomas that can now be analyzed for molecular and protein biomarkers by flow cytometry. Included in the deal are: IncellDx’s patented single-cell assays for quantifying PD-L1 on tumor cells and immune cell subtypes; patented single-cell assay for HPV E6, E7 mRNA detection in cervical samples; and, its incellPREP single-cell preparation kit for solid tissues including tumors.

Researchers at AIIMS, New Delhi have completed a successful study utilizing IncellDx’s next generation (3Dx) investigational molecular assay which quantifies E6, E7 mRNA overexpression in single cells simultaneously with the measurement of cell cycle and cell proliferation, the hallmark of progressive disease.

Praveen Gupta, Managing Director of Premas Life Sciences commented: “India’s molecular diagnostics market needs a refreshing change with IncellDx’s OncoTect assays that offer revolutionary single cell proteomic and genomics marker based diagnostics and more importantly a prognostic solution for early detection and staging for cancer patients with more targeted immuno-onco therapies. India’s cancer burden is increasing and IncellDx offers a perfect path for highly effective companion diagnostics not just to researchers but also to patients. We are indeed delighted to be a part of this change.”

Bruce Patterson MD, CEO of IncellDx commented: “We are excited about this opportunity to bring molecular testing to the flow cytometry field in a region of the world with a great appetite for innovation in the molecular space. The hallmark of cancer research is the quantification of oncogenes and the downstream effects on cell cycle which we have incorporated into a clinical assay. However, as cytology samples contain a heterogeneous mixture of normal and abnormal cells, it is critical that we are able to carry out quantification at the single cell level.”

IncellDx is a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, the company’s focus is on critical life threatening diseases in the areas of cancer, specifically lung, cervical, head and neck, bladder, cancers. http://incelldx.com/

View source version on businesswire.com: http://www.businesswire.com/news/home/20180116006936/en/

CONTACT

IncellDx, Inc.
Chris Meda, CBO
Chrism@incelldx.com
or
Premas
Life Sciences Pvt., Ltd.
Nitesh Shrivastava
nitesh@premaslifesciences.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 医疗技术领袖将在世界患者安全科技峰会上讨论开放数据
  • 世界患者安全・科学・技術サミットで医療技術リーダーがオープンデータについて議論
  • 世界患者安全峰会虽然额满,但分组讨论会仍有空位,分组讨论会将于世界峰会次日在伦敦皇家学会召开
  • SPIRIT DSP: VideoMost® Helps Anet in Japan with Telemedicine and Enterprise Sales
  • 武田宣布其获2018全球杰出雇主认证